Inspire Medical Systems, Inc. (INSP) Navigates Market Pressure from GLP-1 Drugs, Plans 2026 Growth

Core Insights - Inspire Medical Systems, Inc. is facing challenges in the commercial rollout of its new Inspire V system, impacting revenue growth in 2025 due to delays in onboarding treatment centers and reimbursement processes [2][3] - The company is experiencing increased competition from GLP-1 drugs, which are FDA-approved for weight management and obstructive sleep apnea treatment, leading to reduced demand for its implantable devices [3] - Inspire has revised its 2025 sales forecast to a range of $900–$910 million, with CEO Tim Herbert indicating that the slower U.S. commercial launch and transition to Inspire V will affect annual financial performance [3] Company Developments - Despite current challenges, Inspire Medical Systems' Board has authorized a $200 million share buyback plan, indicating confidence in the company's long-term prospects [4] - The company plans a marketing push and expansion of treatment centers in the second half of 2025, which could enhance procedure volumes and revenue growth into 2026 [4] - CFO Rick Buchholz announced plans to transition to an advisory role at year-end to ensure a smooth leadership transition [4]